Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Avadel Pharmaceuticals Plc ADR (AVDL)

Avadel Pharmaceuticals Plc ADR (AVDL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 465,838
  • Shares Outstanding, K 58,596
  • Annual Sales, $ 22,330 K
  • Annual Income, $ 7,030 K
  • 60-Month Beta 1.31
  • Price/Sales 20.94
  • Price/Cash Flow N/A
  • Price/Book 4.00
Trade AVDL with:

Options Overview

Details
  • Implied Volatility 113.53%
  • Historical Volatility 28.50%
  • IV Percentile 75%
  • IV Rank 43.49%
  • IV High 186.22% on 01/25/21
  • IV Low 57.59% on 07/06/21
  • Put/Call Vol Ratio 0.13
  • Today's Volume 3,035
  • Volume Avg (30-Day) 1,154
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 20,138
  • Open Int (30-Day) 18,398

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.38
  • Number of Estimates 6
  • High Estimate -0.33
  • Low Estimate -0.49
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -90.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.28 +9.20%
on 08/19/21
8.50 -6.47%
on 08/27/21
+0.44 (+5.86%)
since 08/17/21
3-Month
6.35 +25.20%
on 07/19/21
8.50 -6.47%
on 08/27/21
+0.10 (+1.27%)
since 06/17/21
52-Week
4.83 +64.60%
on 09/24/20
10.32 -23.00%
on 03/15/21
+2.04 (+34.52%)
since 09/17/20

Most Recent Stories

More News
Avadel Pharmaceuticals Announces Publication of Data from Pivotal Phase 3 REST-ON Trial of FT218 in Adults with Narcolepsy in SLEEP

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness (EDS) and cataplexy...

AVDL : 7.95 (-0.38%)
Avadel: Q2 Earnings Snapshot

DUBLIN (AP) _ Avadel Pharmaceuticals PLC (AVDL) on Monday reported a second-quarter loss of $19.6 million, after reporting a profit in the same period a year earlier.

AVDL : 7.95 (-0.38%)
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results

-- Presentation of post hoc analyses from pivotal REST-ON clinical trial at SLEEP 2021 further support positive primary and secondary endpoint data for all evaluated doses of FT218, beginning as early...

AVDL : 7.95 (-0.38%)
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company primarily focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness...

AVDL : 7.95 (-0.38%)
Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy...

AVDL : 7.95 (-0.38%)
Myasthenia Gravis Treatment Market Size, Share, Trends, Analysis and Forecast 2027

The report on Myasthenia Gravis Treatment provides the clients with a comprehensive analysis of crucial driving factors, consumer behavior, growth trends, product utilization, key player analysis, brand...

ARGX : 331.67 (+2.50%)
ALPMF : 17.2500 (+0.88%)
AVDL : 7.95 (-0.38%)
BAX : 83.61 (+0.47%)
GSK : 38.93 (-0.46%)
GRFS : 15.39 (+6.51%)
MTZPY : 18.6000 (-0.13%)
NVS : 83.48 (-1.07%)
RARX : 48.00 (-0.03%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Avadel to Present New Efficacy and Safety Data from Pivotal Phase 3 REST-ON Trial of FT218 at SLEEP 2021

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy...

AVDL : 7.95 (-0.38%)
Avadel Pharmaceuticals Expands Leadership Team with Three Strategic Hires

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy...

AVDL : 7.95 (-0.38%)
Avadel Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy...

AVDL : 7.95 (-0.38%)
Avadel: Q1 Earnings Snapshot

DUBLIN (AP) _ Avadel Pharmaceuticals PLC (AVDL) on Monday reported a loss of $13.4 million in its first quarter.

AVDL : 7.95 (-0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates...

See More

Key Turning Points

3rd Resistance Point 8.45
2nd Resistance Point 8.27
1st Resistance Point 8.11
Last Price 7.95
1st Support Level 7.77
2nd Support Level 7.59
3rd Support Level 7.43

See More

52-Week High 10.32
Fibonacci 61.8% 8.23
Last Price 7.95
Fibonacci 50% 7.58
Fibonacci 38.2% 6.93
52-Week Low 4.83

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar